Skip to main content

Hitting a Home Run for Small-Cell Lung Cancer Patients

By: NewsUSA

(NewsUSA) - Not long ago, small cell lung cancer was considered the forgotten cancer, and treatment was generally chemotherapy and radiation. But now, there is a new treatment that is showing great promise for patients with small-cell lung cancer. Some doctors say that when it works, it is like hitting a home run in treating small-cell lung cancer.

This exciting new treatment uses the patient's immune system to fight cancer. The treatment, called T-cell engager technology, uses the immune system's T-cells to attack and kill the cancer cell. The FDA approved a new T-cell engager therapy last month. 

Dr. Jacob Sands, Thoracic Oncologist at Dana-Farber Cancer Institute, says utilizing T-cell engager technology is like hitting a home run in treating small-cell lung cancer. 

 

Dr. Jacob

 

Dr. Jacob Sands, Thoracic Oncologist at Dana-Farber Cancer Institute

"Chemotherapy can be like swinging the bat for a single or a double. You're more likely to get a hit, but it doesn't necessarily win the game. What we've seen from the T-cell engagers is particularly exciting because the numbers suggest a more frequent hit. The question is, are those home runs? We don't yet know. Are they triples? We'll have to see," said Dr. Jacob Sands, Thoracic Oncologist at Dana-Farber Cancer Institute in Boston. 

LCFA encourages people living with small-cell lung cancer to ask their doctor about the latest treatment options.

For more information on T-cell engager technology and small-cell lung cancer at LCFAmerica.org  


 

 

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.03
+5.55 (2.56%)
AAPL  262.77
+0.53 (0.20%)
AMD  238.03
-2.53 (-1.05%)
BAC  51.52
-0.52 (-1.00%)
GOOG  251.34
-5.68 (-2.21%)
META  733.27
+1.10 (0.15%)
MSFT  517.66
+0.87 (0.17%)
NVDA  181.16
-1.48 (-0.81%)
ORCL  275.15
-2.03 (-0.73%)
TSLA  442.60
-4.83 (-1.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.